Share on StockTwits
 

Gilead Sciences (NASDAQ:GILD)‘s stock had its “positive” rating reaffirmed by research analysts at TheStreet in a report released on Wednesday, Analyst Ratings Net reports.

The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”

Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.39% during mid-day trading on Wednesday, hitting $74.6999. The stock had a trading volume of 1,890,953 shares. Gilead Sciences has a 1-year low of $38.27 and a 1-year high of $76.11. The stock has a 50-day moving average of $73.63 and a 200-day moving average of $65.31. The company has a market cap of $114.5 billion and a P/E ratio of 41.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter last year, the company posted $1.00 earnings per share. Gilead Sciences’s revenue was up 14.7% compared to the same quarter last year. Analysts expect that Gilead Sciences will post $2.00 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Nomura initiated coverage on shares of Gilead Sciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Separately, analysts at UBS AG reiterated a “buy” rating on shares of Gilead Sciences in a research note to investors on Monday, January 6th. They now have a $102.00 price target on the stock, up previously from $80.00. Finally, analysts at Citigroup Inc. raised their price target on shares of Gilead Sciences to $96.00 in a research note to investors on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $79.76.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.